Pfizer Explores Gene Markers' Ability to Predict Axitinib Response in Kidney Cancer
September 28, 2011
Pfizer Explores Gene Markers' Ability to Predict Axitinib Response in Kidney Cancer
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- New VEGF Biomarker Data Illustrates Complexities of Personalizing Anti-Angiogenic Drugs
September 28, 2011 / Pharmacogenomics Reporter - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - Alzheimer's Prevention Study in Genetically Defined High-Risk Patients Includes Roche, Lilly Drugs
October 10, 2012 / Pharmacogenomics Reporter - Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 1, 2012 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter